{{Rsnum
|rsid=1344142
|Gene=ARHGEF3
|Chromosome=3
|position=56823405
|Orientation=minus
|GMAF=0.4761
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ARHGEF3
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 28.3 | 41.6 | 30.1
| HCB | 54.0 | 38.7 | 7.3
| JPT | 44.2 | 46.0 | 9.7
| YRI | 19.7 | 57.8 | 22.4
| ASW | 26.3 | 42.1 | 31.6
| CHB | 54.0 | 38.7 | 7.3
| CHD | 49.5 | 45.0 | 5.5
| GIH | 23.8 | 51.5 | 24.8
| LWK | 22.7 | 46.4 | 30.9
| MEX | 44.8 | 44.8 | 10.3
| MKK | 29.5 | 47.4 | 23.1
| TSI | 21.6 | 50.0 | 28.4
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1344142
|Name_s=
|Gene_s=ARHGEF3
|Feature=
|Evidence=PubMed ID:18499081
|Annotation=In family-based association tests of women from Australia and the UK, rs1344142 was one of five SNPs that demonstrated significant association with decreased age-adjusted bone mineral density.
|Drugs=
|Drug Classes=
|Diseases=Osteoporosis
|Curation Level=Curated
|PharmGKB Accession ID=PA161748316
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1344142
|overall_frequency_n=69
|overall_frequency_d=128
|overall_frequency=0.539062
|n_genomes=47
|n_genomes_annotated=0
|n_haplomes=64
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}